Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction

Lepore, John J.; Olson, Eric; Demopoulos, Laura; Haws, Thomas; Fang, Zixing; Barbour, April M.; Fossler, Michael; Davila-Roman, Victor G.; Russell, Stuart D.; Gropler, Robert J.

doi:10.1016/j.jchf.2016.01.008

Cited by 165Heart Failure Treatment and ManagementDiabetes Treatment and ManagementCardiovascular Function and Risk Factors

Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction

Open access

Lepore, John J., Olson, Eric, Demopoulos, Laura, Haws, Thomas, Fang, Zixing, Barbour, April M., Fossler, Michael, Davila-Roman, Victor G. +2 more·2016·JACC: Heart Failure

DOI 10.1016/j.jchf.2016.01.008

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure.Background Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes.Methods We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE.Results Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated.Conclusions Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jchf.2016.01.008

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In patients with type 2 diabetes and advanced heart failure, insulin use is independently associated with a significantly worse prognosis.
“In patients with T2DM and advanced HF, insulin use is independently associated with a significantly worse prognosis.552”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [552]
A small randomized, placebo-controlled trial of albiglutide in HFrEF showed no effect on left ventricular function and 6-minute walk distance.
“A small randomized, placebo-controlled trial of albiglutide in HFrEF showed no effect on left ventricular function and 6-minute walk distance.190”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [190]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,218 · see citing works
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,069 · see citing works
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan
Rector, T. S., & Cohn, J. N. (1992) · American Heart Journal · doi:10.1016/0002-8703(92)90986-6 · Cited by 1,020 · see citing works
Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works
Patients' self-assessment of their congestive heart failure : Content, reliability, and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire
Ts, R. (1987) · Medical Entomology and Zoology · Cited by 807 · see citing works
Fatty Acid Oxidation Enzyme Gene Expression Is Downregulated in the Failing Heart
Sack, M. N., Rader, T. A., Park, S., Bastin, J., McCune, S. A., & Kelly, D. P. (1996) · Circulation · doi:10.1161/01.cir.94.11.2837 · Cited by 678 · see citing works
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works
Mitochondrial energy metabolism in heart failure: a question of balance
Huss, J. M., & Kelly, D. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24405 · Cited by 533 · see citing works
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
Graham, D. J., Ouellet‐Hellstrom, R., MaCurdy, T. E., Ali, F. N., Sholley, C., Worrall, C. M., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512 · see citing works
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Paul Steendijk, A., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 471 · see citing works
Energy metabolism in heart failure and remodelling
Ingwall, J. S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn301 · Cited by 462 · see citing works
Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts
Zhao, T., Parikh, P., Bhashyam, S., Bölükoglu, H., Poornima, I. G., Shen, Y., & Shannon, R. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 298 · see citing works
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · see citing works
Myocardial Free Fatty Acid and Glucose Use After Carvedilol Treatment in Patients With Congestive Heart Failure
Wallhaus, T. R., Taylor, M., DeGrado, T. R., Russell, D. C., Stanko, P., Nickles, R. J., & Stone, C. K. (2001) · Circulation · doi:10.1161/01.cir.103.20.2441 · Cited by 253 · see citing works
Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting
Sokos, G. G., Bölükoglu, H., German, J., Hentosz, T. M., Magovern, G. J., Maher, T. D., Dean, D. A., Bailey, S. H., MARRONE, G. C., Benckart, D. H., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.022 · Cited by 253 · see citing works
Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied Hearts
Sorokina, N., O’Donnell, J. M., McKinney, R. D., Pound, K. M., Woldegiorgis, G., LaNoue, K. F., Ballal, K., Taegtmeyer, H., Buttrick, P. M., & Lewandowski, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.668665 · Cited by 193 · see citing works
Total-body and myocardial substrate oxidation in congestive heart failure
Paolisso, G., Gambardella, A., Galzerano, D., D’Amore, A., Rubino, P., Verza, M., Teasuro, P., Varricchio, M., & D’Onofrio, F. (1994) · Metabolism · doi:10.1016/0026-0495(94)90241-0 · Cited by 166 · see citing works
The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure
Ingle, L., Shelton, R. J., Rigby, A. S., Nabb, S., Clark, A. L., & Cleland, J. G. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi259 · Cited by 126 · see citing works
Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?
Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121 · see citing works
Reproducibility of Peak Oxygen Uptake and Other Cardiopulmonary Exercise Testing Parameters in Patients With Heart Failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing)
Bensimhon, D. R., Leifer, E. S., Ellis, S. J., Fleg, J. L., Keteyian, S. J., Piña, I. L., Kitzman, D. W., McKelvie, R. S., Kraus, W. E., Forman, D. E., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.047 · Cited by 116 · see citing works
Self-citation
Rosiglitazone Improves Myocardial Glucose Uptake in Patients With Type 2 Diabetes and Coronary Artery Disease
Läutamaki, R., Airaksinen, J. K. E., Seppänen, M., Toikka, J., Luotolahti, M., Ball, E., Borra, R., Härkönen, R., Iozzo, P., Stewart, M. W., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2787 · Cited by 98 · see citing works
Dependency of Contractile Reserve on Myocardial Blood Flow
Lee, H. H., Dávila‐Román, V. G., Ludbrook, P. A., COURTOIS, M. R., Walsh, J. F., Delano, D. A., Rubin, P. J., & Gropler, R. J. (1997) · Circulation · doi:10.1161/01.cir.96.9.2884 · Cited by 67 · see citing works
Self-citation
Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin
Allard, M. F., Wambolt, R. B., Longnus, S., Grist, M., Lydell, C. P., Parsons, H. L., Rodrigues, B. B., Hall, J. L., Stanley, W. C., & Bondy, G. P. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.3.e487 · Cited by 53 · see citing works
Cardiac efficiency and oxygen consumption measured with 11C-acetate PET after long-term cardiac resynchronization therapy.
Lindner, O., Sørensen, J. C. H., Vogt, J., Fricke, E., Baller, D., Horstkotte, D., & Burchert, W. (2006) · PubMed · Cited by 46 · see citing works
Improvement in the mechanical efficiency of walking: An explanation for the “placebo effect” seen during repeated exercise testing of patients with heart failure
Russell, S. D., McNeer, F. R., Beere, P. A., Logan, L. J., & Higginbotham, M. B. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70350-3 · Cited by 27 · see citing works
Self-citation
Albiglutide
Rosenstock, J., & Stewart, M. W. (2010) · Drugs of the Future · doi:10.1358/dof.2010.035.09.1516042 · Cited by 16 · see citing works
Clinical results with oral milrinone in heart failure
DiBianco, R. (1989) · European Heart Journal · doi:10.1093/eurheartj/10.suppl_c.44 · Cited by 13 · see citing works
Impact of reversible trapping of tracer and the presence of blood metabolites on measurements of myocardial glucose utilization performed by PET and 18F-fluorodeoxyglucose using the Patlak method
Herrero, P., Dence, C. S., Sharp, T. L., Welch, M. J., & Gropler, R. J. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.03.002 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

2 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Rosenstock JR, Stewart M. Albiglutide: glucagon- like peptide GLP-1 receptor agonist treatment of type 2 diabetes. Drugs Future 2010;35:701-12.

Sorted by citations

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642 · see citing works
Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708 · see citing works
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639 · see citing works
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577 · see citing works
Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure
Tassell, B. W. V., Canada, J. M., Carbone, S., Trankle, C. R., Buckley, L. F., Oddi, C., Abouzaki, N. A., Dixon, D. L., Kadariya, D., Christopher, S., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004373 · Cited by 247 · see citing works
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.014 · Cited by 236 · see citing works
Diabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.010 · Cited by 188 · see citing works
European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure
Seferovic, P. M., Coats, A. J. S., Ponikowski, P. P., Filippatos, G. S., Huelsmann, M., Jhund, P. S., Polovina, M. M., Michel Komajda, N., Seferović, J. P., Sarı, İ., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 180 · see citing works
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171 · see citing works
Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139 · see citing works
Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes
Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 130 · see citing works
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106 · see citing works
Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials
von Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 116 · see citing works
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103 · see citing works
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 98 · see citing works
Mitochondrial dysfunction and its impact on diabetic heart
Verma, S. K., Garikipati, V. N. S., & Kishore, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.021 · Cited by 91 · see citing works
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
Neves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., & Ferreira, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 79 · see citing works
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 79 · see citing works
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 77 · see citing works
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70 · see citing works
GLP-1 receptor agonists and heart failure in diabetes
Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 65 · see citing works
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 64 · see citing works
Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy
Moellmann, J., Klinkhammer, B. M., Onstein, J., Stöhr, R., Jankowski, V., Jankowski, J., Lebherz, C., Tacke, F., Marx, N., Boor, P., et al. (2018) · Diabetes · doi:10.2337/db17-1212 · Cited by 60 · see citing works
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 58 · see citing works
Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction
Docherty, K. F., Campbell, R. T., Brooksbank, K. J. M., Dreisbach, J. G., Forsyth, P., Godeseth, R. L., Hopkins, T., Jackson, A. M., Lee, M. M. Y., McConnachie, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054892 · Cited by 56 · see citing works
The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes
Du, X., Zhang, H., Zhang, W., Wang, Q., Wang, W., Ge, G., Bai, J., Guo, X., Zhang, Y., Jiang, X., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105732 · Cited by 55 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 55 · see citing works
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
Kumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54 · see citing works
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 52 · see citing works
Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 49 · see citing works
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 49 · see citing works
Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43 · see citing works
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 43 · see citing works
Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
Wang, J., Yu, M., Xu, J., Cheng, Y., Li, X., Wei, G., Wang, H., Kong, H., & Xie, W. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0496-y · Cited by 42 · see citing works
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42 · see citing works
After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 42 · see citing works
Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35 · see citing works
GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction
Nguyễn, T. D., Shingu, Y., Amorim, P., Schenkl, C., Schwarzer, M., & Doenst, T. (2018) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-018-9795-z · Cited by 41 · see citing works
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34 · see citing works
A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K. K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34 · see citing works
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32 · see citing works
The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
Koška, J., Migrino, R. Q., Chan, K. C., Cooper-Cox, K., & Reaven, P. D. (2021) · Diabetes Care · doi:10.2337/dc20-2014 · Cited by 32 · see citing works
Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
Singh, A., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 32 · see citing works
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32 · see citing works
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29 · see citing works
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 28 · see citing works
Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27 · see citing works
Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 26 · see citing works
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26 · see citing works
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
Nyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 26 · see citing works
Can Glucose-Lowering Medications Improve Outcomes in Non-Diabetic Heart Failure Patients? A Bayesian Network Meta-Analysis
Yeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25 · see citing works
The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis
Merza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 23 · see citing works
Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Zhao, H., Liu, Y., Liu, M., Xu, Y., Ling, Q., Lin, W., Zhang, J., Yan, Z., Ma, J., Li, W., et al. (2023) · Drugs · doi:10.1007/s40265-023-01932-2 · Cited by 24 · see citing works
Cardioprotective Mechanisms of Exenatide in Isoprenaline-induced Myocardial Infarction: Novel Effects on Myocardial α-Estrogen Receptor Expression and IGF-1/IGF-2 System
Darwesh, A. M., El-Azab, M. F., Abogresha, N. M., El-Sayed, N. M., & Moustafa, Y. M. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000557 · Cited by 23 · see citing works
The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
Jobanputra, R., Sargeant, J. A., Almaqhawi, A., Ahmad, E., Arsenyadis, F., Webb, D. R., Herring, L. Y., Khunti, K., Davies, M. J., & Yates, T. (2023) · Obesity Reviews · doi:10.1111/obr.13553 · Cited by 22 · see citing works
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 23 · see citing works
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22 · see citing works
Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 21 · see citing works
Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure
Lopez, P. D., Bhatia, K., Bohra, C., Mahmood, K., Baruch, L., & Eng, C. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.07.012 · Cited by 21 · see citing works
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 21 · see citing works
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 21 · see citing works
Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction
Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21 · see citing works
Sodium‐glucose co‐transporter inhibitors: Medications that mimic fasting for cardiovascular prevention
Giaccari, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13814 · Cited by 21 · see citing works
The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 22 · see citing works
Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?
Nesti, L., & Tricò, D. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.818 · Cited by 19 · see citing works
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
Wallner, M., Biber, M. E., Stolfo, D., Sinagra, G., Benson, L., Dahlström, U., Guðbjörnsdóttir, S., Cosentino, F., Mol, P. G. M., Rosano, G. M. C., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae026 · Cited by 18 · see citing works
Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction
Kyhl, K., Lønborg, J., Hartmann, B., Kissow, H., Poulsen, S. S., Ali, H. H. E., Kjær, A., Dela, F., Engstrøm, T., & Treiman, M. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.009 · Cited by 18 · see citing works
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17 · see citing works
Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16 · see citing works
Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications
Staszewsky, L., Baviera, M., Tettamanti, M., Colacioppo, P., Robusto, F., D'Ettorre, A., Lepore, V., Fortino, I., Bisceglia, L., Attolini, E., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002708 · Cited by 13 · see citing works
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 16 · see citing works
Leveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 16 · see citing works
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 16 · see citing works
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 14 · see citing works
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Vaz-Salvador, P., Adão, R., Vasconcelos, I., Leite-Moreira, A. F., & Brás‐Silva, C. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07306-8 · Cited by 15 · see citing works
Impact of diabetes on cardiopulmonary function: the added value of a combined cardiopulmonary and echocardiography stress test
Pugliese, N. R., Pieroni, A., Biase, N. D., Fiore, V., Nesti, L., Agostoni, P., & Dini, F. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10194-7 · Cited by 13 · see citing works
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 13 · see citing works
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 12 · see citing works
Clinical impact of oral antidiabetic medications in heart failure patients
Palazzuoli, A., Ceccarelli, E., Ruocco, G. M., & Nuti, R. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9669-0 · Cited by 11 · see citing works
GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y.-H. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 10 · see citing works
Positioning Metabolism as a Central Player in the Diabetic Heart
Mereweather, L. J., Aparicio, C. N. M., & Heather, L. C. (2020) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2020.9.1.92 · Cited by 10 · see citing works
Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 10 · see citing works
Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Possibilities of Treatment
Обрезан, А. Г., & Куликов, Н. В. (2018) · Kardiologiia · doi:10.18087/cardio.2018.7.10156 · Cited by 10 · see citing works
Inflammation in Heart Failure: Mechanisms and Therapeutic Strategies
Jiang, Y., Zhou, G., Guo, Y., & Long, Y. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0050 · Cited by 15 · see citing works
Unlocking metabolic flexibility in heart failure with preserved ejection fraction: Bridging fundamental mechanisms to clinical innovation
Xia, J., Nong, Y., Teng, J., Mohammed, S. A., Liu, J., Pang, Y., Costantino, S., Ruschitzka, F. T., Hamdani, N., Abdellatif, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113471 · Cited by 11 · see citing works
Glucose‐lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology
Hong, T., Su, Q., Li, X., Shan, Z., Chen, L., Peng, Y., Chen, L., Yan, L., Bao, Y., Lyu, Z., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3416 · Cited by 9 · see citing works
Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis
Chen, C., Huang, Y., Zeng, Y., Lu, X., & Dong, G. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-01275-5 · Cited by 9 · see citing works
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 10 · see citing works
Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis
Chen, C., Peng, H., Li, M., Lu, X., Huang, M., Zeng, Y., & Dong, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664533 · Cited by 9 · see citing works
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Y., Xu, X.-Z., Liu, J., Wang, P.-Y., Wang, X., Feng, H., Liu, C., & Han, X. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03324-6 · Cited by 8 · see citing works
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 8 · see citing works
Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 8 · see citing works
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 9 · see citing works
Cardiac substrate metabolism in type 2 diabetes
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2025) · Biochemical Journal · doi:10.1042/bcj20240189 · Cited by 6 · see citing works
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
Patel, K. V., Sarraju, A., Neeland, I. J., & McGuire, D. K. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01355-5 · Cited by 6 · see citing works
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes
Mather, K. J., Considine, R. V., Hamilton, L., Patel, N. A., Mathias, C. J., Territo, W. L., Goodwill, A. G., Tune, J. D., Green, M. A., & Hutchins, G. D. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00712 · Cited by 6 · see citing works
Lack of Benefit for Liraglutide in Heart Failure—Reply
Margulies, K. B., McNulty, S. E., & Cappola, T. P. (2016) · JAMA · doi:10.1001/jama.2016.15394 · Cited by 6 · see citing works

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T. P., Szapacs, M. E., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 105 · see citing works
Self-citation
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Halbirk, M., Nørrelund, H., Møller, N., Holst, J. J., Schmitz, O., Nielsen, R. R., Nielsen‐Kudsk, J. E., Nielsen, S. S., Nielsen, T. T., Eiskjær, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00930.2009 · Cited by 164 · see citing works
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works
Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes
Ferreira, J. P., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2660 · Cited by 30 · see citing works
Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
Nielsen, R., Jorsal, A., Iversen, P., Tolbod, L. P., Bouchelouche, K., Sørensen, J., Harms, H. J., Flyvbjerg, A., Tarnow, L., Kistorp, C., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-1000-2 · Cited by 43 · see citing works

Authors: Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J.
Affiliations: GlaxoSmithKline (United States) (US)
Johns Hopkins University (US)
Washington University in St. Louis (US)
Corresponding author: Lepore, John J.
ORCID: Haws, Thomas
Fossler, Michael
Russell, Stuart D.
Gropler, Robert J.
Venue: JACC: Heart Failure
Publisher: Elsevier BV
Published: 2016-07
Volume: 4
Issue: 7
Pages: 559-566
ISSN: 2213-1779 (ISSN-L)
DOI: 10.1016/j.jchf.2016.01.008
OpenAlex: W2335779504
Cited by: 165
References: 31
Citations by year: 2026: 12 · 2025: 18 · 2024: 23 · 2023: 15 · 2022: 12 · 2021: 16 · 2020: 10 · 2019: 18 · 2018: 13 · 2017: 17 · 2016: 11
FWCI: 16.22
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 588 d)
Locations: JACC Heart Failure (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline (NCT01357850)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: albiglutide, GLP-1 receptor agonists, myocardial metabolism, peak oxygen uptake, exercise capacity, left ventricular ejection fraction, cardiac function
MeSH terms: Walk Test, Positron Emission Tomography Computed Tomography, Adult, Aged, Carbon Radioisotopes, Chronic Disease, Echocardiography, Female, Glucose, Heart Failure, Humans, Male, Middle Aged, Myocardium, Oxygen Consumption, Quality of Life, Stroke Volume, Exercise Tolerance, Radiopharmaceuticals, Fluorodeoxyglucose F18, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks